[1]McMurray John J V et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J].European ...
北京时间9月1日21:38,格拉斯哥大学心血管与医学科学研究中心-心血管研究中心的John McMurray教授在ESC(欧洲心脏病学会年会)正式公布了DAPA-HF(达格列净预防心衰不良结局研究)的结果。 DAPA-HF:划时代的研究结果 DAPA-HF是首个在伴或不伴2型糖尿病的射血分数降低心衰患者中应用SGLT2抑制剂治疗的心衰结局研究。研究...
The DAPA-HF trial substantially extends the benefits of SGLT2 inhibitors in slowing the evolution and progression of heart failure, particularly in patients with a reduced ejection fraction. To date, five large-scale trials (...
[1]McMurray John J V et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J].European journal of heart failure, 2019, 21(5): 66...
The DAPA-HF trial evaluated the safety and efficacy of dapagliflozin in patients with HF with reduced ejection fraction regardless of the presence of diabetes. It was an international, multi-center, randomized, placebo-controlled study, with blinding of patients and all study personnel, a low ...
我们在两项试验的事后分析中检验了这一方法,这两项试验比较了达格列嗪与安慰剂对射血分数降低(DAPA-HF)和射血分数轻度降低或维持(Deliver)的心力衰竭患者的疗效。我们评估了达格列嗪对分级复合肾脏结局的影响,包括:(1)全因死亡率;(2)终末期肾脏病;(3)肾小球滤过率估计值(EGFR)下降≥57%;(4)EGFR下降≥50%...
3月31日,JAMA子刊——JAMA Cardiology在线发表了DAPA-HF研究(the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial)的新进展。 本次发布的研究结果旨在探索与安慰剂相比,SGLT-2抑制剂达格列净应用于射血分数降低的心衰(HFrEF)患者的疗效和安全性。 研究简介 该研究是一项在全球20个国家、...
The drug had also been shown, in the recentDEFINE-HFtrial, to improve symptoms and quality of life in a similar HF population, again in patients with or without diabetes. SGLT2 inhibitor benefits for HF endpoints in patients who primarily have diabetes have already been established. ...
科室小讲座 DAPAHF解读(1)钠-葡萄糖共转运体-2抑制剂(SGLT-2i)在心力衰竭中的治疗进展 历时20多年，糖尿病管理指南迭代更新逐步走向以心血管结局为中心T2DM管理时代 风险预防探讨心血管安全性存疑 1990 2000 20072008 CV事件不尽人意 2009 2010 2015 2016 新的曙光 2017201820192020 DCCTUKPDS控制血糖可减少糖尿 病...
[2]Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure. Retrieved August 20, 2019, from网页链接 [3]Farxiga’s DAPA-HF trial at ESC. Retrieved September 1, 2019, from网页链接...